CN103635570A - 表达人h-铁蛋白的重组酵母 - Google Patents

表达人h-铁蛋白的重组酵母 Download PDF

Info

Publication number
CN103635570A
CN103635570A CN201280024378.4A CN201280024378A CN103635570A CN 103635570 A CN103635570 A CN 103635570A CN 201280024378 A CN201280024378 A CN 201280024378A CN 103635570 A CN103635570 A CN 103635570A
Authority
CN
China
Prior art keywords
ferritin
iron
disorder
yeast
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280024378.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·康纳
R·L·凯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHYNA LLC
Original Assignee
CHYNA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHYNA LLC filed Critical CHYNA LLC
Publication of CN103635570A publication Critical patent/CN103635570A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280024378.4A 2011-05-24 2012-05-24 表达人h-铁蛋白的重组酵母 Pending CN103635570A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/114429 2011-05-24
US13/114,429 US8778878B2 (en) 2007-01-29 2011-05-24 Use of ferritin to treat iron disorders
PCT/GB2012/000461 WO2012160333A2 (en) 2011-05-24 2012-05-24 Recombinant yeast

Publications (1)

Publication Number Publication Date
CN103635570A true CN103635570A (zh) 2014-03-12

Family

ID=46317426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280024378.4A Pending CN103635570A (zh) 2011-05-24 2012-05-24 表达人h-铁蛋白的重组酵母

Country Status (12)

Country Link
US (1) US8778878B2 (enExample)
EP (1) EP2714888B1 (enExample)
JP (1) JP2014516535A (enExample)
CN (1) CN103635570A (enExample)
AU (1) AU2012260682B2 (enExample)
BR (1) BR112013029769B1 (enExample)
CA (1) CA2874042C (enExample)
DK (1) DK2714888T3 (enExample)
ES (1) ES2659185T3 (enExample)
NO (1) NO2714888T3 (enExample)
PL (1) PL2714888T3 (enExample)
WO (1) WO2012160333A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759986A (zh) * 2019-10-18 2020-02-07 大连工业大学 一种可逆自组装蛋白的高效制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
PT1973549T (pt) 2006-01-06 2016-10-25 Luitpold Pharm Inc Métodos e composições para administração de ferro
US8778878B2 (en) * 2007-01-29 2014-07-15 Chyna, LLC Use of ferritin to treat iron disorders
WO2016027264A1 (en) * 2014-08-21 2016-02-25 Ramot At Tel-Aviv University Ltd. Targeted liposomes encapsulating iron complexes and their uses
KR101811050B1 (ko) * 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
CN108503704A (zh) 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
CA3102319A1 (en) * 2018-06-04 2019-12-12 Sidero Bioscience, Llc Compositions and methods for improvement of iron metabolism and gut microbiome health
EP3976636B1 (en) * 2019-05-28 2025-05-21 PreviPharma Consulting GmbH Method for preparing iron-depleted ferritin and use thereof
MX2023013641A (es) * 2021-05-19 2024-02-16 Sidero Bioscience Llc Tolerabilidad de la composicion de ferritina.
KR102691733B1 (ko) * 2021-10-13 2024-08-05 전북대학교산학협력단 효모 유래 액포를 유효성분으로 포함하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040695A1 (en) * 2000-11-15 2002-05-23 Rna Inc. Method for mass-producing human ferritin using recombinant nethylotropic yeasts
KR20040087539A (ko) * 2003-04-08 2004-10-14 김대혁 이종중합형 패리틴 생산방법
WO2007099231A1 (fr) * 2006-03-01 2007-09-07 V. Mane Fils Systeme d'expression d'un gene d'interet chez la levure
CN102065686A (zh) * 2008-03-28 2011-05-18 西纳有限责任公司 铁蛋白用于治疗缺铁性障碍的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778878B2 (en) * 2007-01-29 2014-07-15 Chyna, LLC Use of ferritin to treat iron disorders
US8071542B2 (en) * 2007-01-29 2011-12-06 Chyna, LLC Use of ferritin to treat iron deficiency disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040695A1 (en) * 2000-11-15 2002-05-23 Rna Inc. Method for mass-producing human ferritin using recombinant nethylotropic yeasts
KR20040087539A (ko) * 2003-04-08 2004-10-14 김대혁 이종중합형 패리틴 생산방법
WO2007099231A1 (fr) * 2006-03-01 2007-09-07 V. Mane Fils Systeme d'expression d'un gene d'interet chez la levure
CN102065686A (zh) * 2008-03-28 2011-05-18 西纳有限责任公司 铁蛋白用于治疗缺铁性障碍的用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H.-Y. SEO ET AL: "Enhanced expression and functional characterization of the human ferritin H- and L-chain genes in Saccharomyces cerevisiae", 《APPL MICROBIOL BIOTECHNOL》 *
INGE VAN ROOY ET AL: "Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain", 《JOURNAL OF CONTROLLED RELEASE》 *
O′SCAR HERRERO 等: "Engineering the Saccharomyces cerevisiae isoprenoid pathway for de novo production of aromatic monoterpenes in wine．", 《METABOLIC ENGINEERING》 *
YOUNG-MI SHIN ET AL: "Enhanced Iron Uptake of Saccharomyces cerevisiae by Heterologous Expression of a Tadpole Ferritin Gene", 《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》 *
YU-JUNG CHANG ET AL: "Recovery from iron deficiency in rats by the intake of recombinant yeast producing human H-ferritin", 《NUTRITION》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759986A (zh) * 2019-10-18 2020-02-07 大连工业大学 一种可逆自组装蛋白的高效制备方法
CN110759986B (zh) * 2019-10-18 2023-01-31 大连工业大学 一种可逆自组装蛋白的高效制备方法

Also Published As

Publication number Publication date
CA2874042C (en) 2020-10-06
NO2714888T3 (enExample) 2018-03-24
US20110287033A1 (en) 2011-11-24
BR112013029769B1 (pt) 2021-09-28
EP2714888B1 (en) 2017-10-25
WO2012160333A2 (en) 2012-11-29
BR112013029769A2 (pt) 2017-06-06
EP2714888A2 (en) 2014-04-09
ES2659185T3 (es) 2018-03-14
WO2012160333A3 (en) 2013-03-07
CA2874042A1 (en) 2012-11-29
AU2012260682B2 (en) 2015-07-30
AU2012260682A1 (en) 2013-05-02
JP2014516535A (ja) 2014-07-17
PL2714888T3 (pl) 2018-06-29
DK2714888T3 (da) 2018-01-29
US8778878B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
CN103635570A (zh) 表达人h-铁蛋白的重组酵母
US8071542B2 (en) Use of ferritin to treat iron deficiency disorders
AU2008353469B2 (en) Use of ferritin to treat iron deficiency disorders
US20230414709A1 (en) Mutant ngal proteins and uses thereof
US8795627B2 (en) Treatment of liver disorders by administration of RAP conjugates
US12173037B1 (en) Mutant NGAL proteins and uses thereof
US20210100916A1 (en) Preparation and use of mitochondrion-targeting self-assembled protein nanoparticle
JP2021508037A (ja) クロトータンパク質レベルを評価および改善するための製品および方法
CN110302362B (zh) 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用
WO2025167587A1 (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
US20170298108A1 (en) Compositions comprising grim-19 therapeutics and methods of use
JP2014132029A (ja) 鉄欠乏性障害を治療するためのフェリチンの使用
KR101471245B1 (ko) Ａ형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물
Li et al. Elevated COMMD1 Contributes to Cardiomyocyte Copper Efflux in Chronic Myocardial Ischemia: Insights From Rhesus Monkey
US20230331780A1 (en) Compositions and methods for the treatment of alzheimer's disease
Kuliyev Functional and Biochemical Characterization of ZIP4 Extracellular Domain⎯ Implications on Acrodermatitis Enteropathica, a Life-Threatening Genetic Disorder
Holgado et al. Iron Metabolism: New Biomarkers Implicated
Evans et al. Multiple biological activities of human recombinant interleukin 1. C. A. Dinarello, J. G. Cannon, JW Mier
Walker Biology and receptor interactions of P97 and the transferrin receptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140312